Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852558 | 0.91 | KMT2A (0.54) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14557208 | 0.89 | KLK7 (0.57) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5123962 | 0.86 | KDM4E (0.64) | KMT2AMEN1CYP1A2ALDH1A1HPGD | |
| SCHEMBL8395426 | 0.84 | SIRT1 (0.65) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL4152854 | 0.84 | KMT2A (0.48) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3852327 | 0.83 | HPGD (0.54) | KMT2AMEN1ALDH1A1HPGDMAPT | |
| SCHEMBL11440392 | 0.83 | FTO (0.71) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8671343 | 0.83 | KLK7 (0.51) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3134908 | 0.82 | MEN1 (1.00) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21572660 | 0.81 | FTO (0.64) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | claimed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | claimed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | KMT2A 4267/4885MEN1 3865/4885CYP1A2 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.